Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Chimerix Inc (CMRX) USD0.001

Sell:$1.33 Buy:$1.34 Change: $0.005 (0.37%)
NASDAQ:0.05%
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$1.33
Buy:$1.34
Change: $0.005 (0.37%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$1.33
Buy:$1.34
Change: $0.005 (0.37%)
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Chimerix, Inc. is a biotechnology company. The Company is focused on discovering, developing and commercializing medicines that address unmet medical needs. Its lead compound, brincidofovir, is in development as an oral and intravenous (IV) formulation for the prevention and treatment of deoxyribonucleic acid (DNA) viruses, including smallpox, adenoviruses (AdV), and the human herpesviruses. It is also advancing the development of CMX521 for the treatment and prevention of norovirus. In addition, the Company has an active discovery program focusing on viral targets for which limited or no therapies are available. Brincidofovir is an investigational oral nucleotide analog that has shown spectrum antiviral activity against all five families of double-stranded deoxyribonucleic acid (dsDNA) viruses that affect humans. Oral and IV formulations of brincidofovir are in development, both of which deliver the active antiviral directly to the site of viral replication.

Contact details

Address:
2505 Meridian Pkwy Ste 100
DURHAM
27713-2288
United States
Telephone:
+1 (919) 8061074
Website:
www.chimerix.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
CMRX
ISIN:
US16934W1062
Market cap:
$89.45 million
Shares in issue:
61.27 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Martha Demski
    Chairman of the Board
  • Michael Sherman
    Chief Executive Officer
  • Michael Andriole
    Chief Financial Officer, Chief Business Officer
  • Michael Alrutz
    Senior Vice President, General Counsel
  • Roy Ware
    Chief Manufacturing and Technology Officer
  • David Jakeman
    Principal Accounting Officer, Executive Director of Finance and Accounting
  • Heather Knight-Trent
    Vice President - Regulatory Affairs
  • Randall Lanier
    Chief Science Officer
  • Williams Nichols
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.